Literature DB >> 16626873

Chronic treatment with first or second generation antipsychotics in rodents: effects on high affinity nicotinic and muscarinic acetylcholine receptors in the brain.

A V Terry1, D A Gearhart, S P Mahadik, S Warsi, J L Waller.   

Abstract

Several postmortem and neuroimaging studies suggest that central nicotinic and muscarinic acetylcholine receptors are important in both the pathophysiology and pharmacotherapy of schizophrenia. However, while antipsychotic drugs are routinely used in the therapeutics of schizophrenia, little is known about their effects on the densities of these receptors when they are administered for extended periods of time (a common practice in the clinical setting). In the present study in rats, the residual effects of prior chronic exposure to representative first generation antipsychotics and second generation antipsychotics on the densities of high affinity nicotinic acetylcholine receptors and muscarinic acetylcholine receptor in the brain were investigated. Test subjects were treated with the first generation antipsychotics, haloperidol (2.0 mg/kg/day) or chlorpromazine (10.0 mg/kg/day) or the second generation antipsychotics, risperidone (2.5 mg/kg/day) or olanzapine (10.0 mg/kg/day) in drinking water for periods of 90 or 180 days, given a drug-free washout period (i.e. returned to normal drinking water) for two weeks and then killed. Quantitative receptor autoradiography was subsequently performed using 16 mum sagittal slices of whole brain incubated with [3H]-epibatidine, [3H]-pirenzepine or [3H]-AFDX-384 to measure high affinity nicotinic acetylcholine receptors, M1 and M2 muscarinic acetylcholine receptors, respectively. The most notable experimental result was a moderate, but significant (P<0.01) increase in [3H]-AFDX-384 binding sites in a number of brain regions (including cortex, hippocampus, subiculum, substantia innominata, and thalamus) associated with prior exposure to olanzapine for 90, but not 180 days. Olanzapine was also associated with a significantly higher density of [3H]-pirenzepine binding sites in cortex lamina I after 90 days of prior drug exposure. These data indicate that chronic treatment with a commonly used second generation antipsychotic, olanzapine is associated with modest increases in M2 muscarinic acetylcholine receptors in memory-related brain regions that may eventually abate with longer periods of chronic drug exposure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16626873     DOI: 10.1016/j.neuroscience.2006.03.011

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  12 in total

Review 1.  Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.

Authors:  Manoranjan S D'Souza; Athina Markou
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

2.  Simultaneous determination of five antipsychotic drugs in rat plasma by high performance liquid chromatography with ultraviolet detection.

Authors:  Guodong Zhang; Alvin V Terry; Michael G Bartlett
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-05-26       Impact factor: 3.205

3.  Neuroleptics and animal models: feasibility of oral treatment monitored by plasma levels and receptor occupancy assays.

Authors:  Emma Perez-Costas; Paolo Guidetti; Miguel Melendez-Ferro; Joyce J Kelley; Rosalinda C Roberts
Journal:  J Neural Transm (Vienna)       Date:  2008-01-11       Impact factor: 3.575

4.  Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol.

Authors:  Adi Malkoff; Abraham Weizman; Illana Gozes; Moshe Rehavi
Journal:  J Neural Transm (Vienna)       Date:  2008-09-20       Impact factor: 3.575

5.  Low levels of muscarinic M1 receptor-positive neurons in cortical layers III and V in Brodmann areas 9 and 17 from individuals with schizophrenia.

Authors:  Elizabeth Scarr; Shaun Hopper; Valentina Vos; Myoung Suk Seo; Ian Paul Everall; Timothy Douglas Aumann; Gursharan Chana; Brian Dean
Journal:  J Psychiatry Neurosci       Date:  2018-08       Impact factor: 6.186

6.  Changes in BQCA Allosteric Modulation of [(3)H]NMS Binding to Human Cortex within Schizophrenia and by Divalent Cations.

Authors:  Brian Dean; Shaun Hopper; P Jeffrey Conn; Elizabeth Scarr
Journal:  Neuropsychopharmacology       Date:  2015-10-29       Impact factor: 7.853

7.  Lower ß2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia.

Authors:  Deepak Cyril D'Souza; Irina Esterlis; Michelle Carbuto; Maegan Krasenics; John Seibyl; Frederic Bois; Brian Pittman; Mohini Ranganathan; Kelly Cosgrove; Julie Staley
Journal:  Am J Psychiatry       Date:  2012-03       Impact factor: 18.112

8.  Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue.

Authors:  Guodong Zhang; Alvin V Terry; Michael G Bartlett
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-08-17       Impact factor: 3.205

9.  In vivo evidence for β2 nicotinic acetylcholine receptor subunit upregulation in smokers as compared with nonsmokers with schizophrenia.

Authors:  Irina Esterlis; Mohini Ranganathan; Frederic Bois; Brian Pittman; Marina R Picciotto; Lara Shearer; Alan Anticevic; Jon Carlson; Mark J Niciu; Kelly P Cosgrove; D Cyril D'Souza
Journal:  Biol Psychiatry       Date:  2013-11-13       Impact factor: 13.382

10.  The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia.

Authors:  Sophia Vinogradov; Melissa Fisher; Heather Warm; Christine Holland; Margaret A Kirshner; Bruce G Pollock
Journal:  Am J Psychiatry       Date:  2009-07-01       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.